U.S. License Holder:
EMD Serono Inc.
Date of License:
March-23-2017 / May-09-2017
BAVENCIO (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for:
Merkel Cell Carcinoma (MCC): Adults and pediatric patients 12 years and older with metastatic MCC;
Urothelial Carcinoma (UC): (I) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy; (II) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy; Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy;
Renal Cell Carcinoma (RCC): First-line treatment, in combination with axitinib of patients with advanced RCC.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
9,402,899 (Immunopotentiative Composition)
Bristol-Myers Squibb Co.; E.R. Squibb and Sons LLC; Ono Pharmaceutical Co., Ltd.; Tasuku Honjo
EMD Serono, Inc.; Merck KGaA; Pfizer Inc.
Stipulated Dismissal Due to Settlement